News >

Novel Approaches to Build on Checkpoint Inhibition in GI Cancers

Jason M. Broderick @jasoncology
Published: Wednesday, Apr 01, 2020

Neeha Zaidi, MD

Neeha Zaidi, MD

Despite some success stories, most gastrointestinal (GI) cancers do not respond to single-agent, or even double-agent, immune checkpoint inhibition, Neeha Zaidi, MD, said in a presentation during the 5th Annual School of Gastrointestinal Oncology™ (SOGO®) conference.
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x